AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall...


AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall Street analysts, saying the drugmaker needs a "transformational deal" to return it to profit growth. A deal for Shire (SHPG +0.2%) or Forest Labs (FRX +0.7%) would rival its's $15B acquisition of MedImmune in 2007. SHPG could help fill the gap with patent-protected medicines for rare diseases and leading ADD therapies, says Kepler Capital Markets, while FRX's lung treatment would bolster the company's respiratory business.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs